PRINCETON, N.J., Dec. 7, 2021 /PRNewswire/ -- Guerbet LLC,
the US affiliate of Guerbet, a global leader in medical
imaging, announced today that Shields Health Care Group, New
England's largest and most advanced provider of diagnostic imaging,
will introduce Guerbet's OptiStar®
Elite injectors system across their network. This procurement
is one the largest in Guerbet's history.
"Guerbet's reputation for innovation, patient safety, and
excellent customer service were important considerations," says
Steve Brune, Field Service Manager
of ProCare (Shields' medical equipment division). "The team at
Guerbet is constantly working to improve and develop new medical
imaging solutions to provide better outcomes, better care, and the
best experience for patients, key reasons why this collaboration
works for us."
The OptiStar Elite MR contrast delivery system offers
enhancements in:
- Workflow efficiency
- Battery-free operation
- Ability to fill syringes in the control room
- Three mounting options including pedestal, ceiling, and
mobile
Mike Yuja, Guerbet's Head of
Sales in North America, says, "We
are proud to partner with Shields to provide our OptiStar Elite
injectors. The reliability and minimal maintenance requirements of
these devices, as well as the seamless installation program make
them an ideal choice for multi-facility implementation.
80% of the OptiStar Elite injectors ordered have already been
installed across Shields' facilities in New England, with the
remaining injectors being installed in early 2022.
About Guerbet
At Guerbet, we build lasting relationships so that we enable
people to live better. This is our purpose. We are a leader in
medical imaging worldwide, offering a wide range of pharmaceutical
products, medical devices, digital and AI solutions for diagnostic
and interventional imaging. A pioneer since 95 years in the field
of contrast media with over 2,600 people globally, we are
continuously innovating with 10% of revenue dedicated to Research
& Development and four centers in France, Israel, and the
United States. Guerbet (GBT) is listed on Euronext Paris
(segment B – mid-caps) and generated €712 million in revenue in
2020. For more information, please visit
www.guerbet-us.com.
About OptiStar® Elite MR Contrast Delivery
System
The OptiStar Elite MR Contrast Delivery System is a Class
II Medical Device in the United
States. For complete information about precautions and
optimal usage conditions for this device, consult the full
instructions for use supplied with each device or with your local
Guerbet representative(s).
Caution: US Federal Law restricts this device to sale by or on
the order of a physician.
About Shields Health Care Group
At Shields, improving lives and elevating performance are at the
heart of everything we do. That's why more health system leaders
trust Shields to help them elevate and scale clinical, operational,
and financial performance. Not just within specialty pharmacy, but
throughout the entire health system. Working alongside your team,
Shields leverages its proven collaborative care model; integrated
care technologies; and dedicated teams to produce the superior
outcomes your patients deserve and the financial results your health
system demands. Together, we elevate performance where it matters
most — expanding payer and drug access; improving therapy
management and care coordination; delivering unsurpassed patient
experiences, and generating the net operating income you need to
accelerate growth. Learn more about how Shields elevates outcomes
and performance at shieldshealthsolutions.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/top-medical-imaging-company-and-provider-of-diagnostic-imaging-collaborate-to-elevate-patient-experience-and-lower-cost-of-care-301432021.html
SOURCE Guerbet